PSILORIS — Psilocybin Research and Information StandardsPSILOPsilocybinRResearchIInformationSStandards

High-quality trials in cancer-related anxiety and a dedicated Phase 2 GAD program show clinically meaningful anxiolytic signals. Meta-analyses support post-acute anxiety reductions, while primary panic disorder remains understudied and is tracked separately.

Multiple modern trials show rapid and clinically meaningful antidepressant effects from psilocybin-assisted therapy, especially in major depression and treatment-resistant depression, though access, durability, and safety monitoring remain active research questions.

A small early pilot reported acute OCD symptom reductions after psilocybin, and modern challenge/open-label protocols are now underway. Dedicated controlled efficacy trials remain limited, so PSILORIS keeps OCD as a candidate indication.

Dedicated controlled trials of psilocybin for primary panic disorder are largely absent. Current material is limited to comorbid observations, public-health toxicology noting acute panic provocation risk, and theoretical mechanistic discussion.

Psilocybin is a biologically and psychologically plausible candidate for PTSD, but dedicated large-scale psilocybin PTSD trials lag behind MDMA-assisted therapy research. Current support is mostly mechanistic, early-phase, or extrapolated.

Current clinical consensus treats personal or strong family history of psychotic disorders as a major exclusion criterion for psilocybin therapy. Available evidence does not support benefit and highlights elevated risk of harm.

Randomised and pilot data suggest psilocybin-assisted psychotherapy can reduce heavy drinking and support smoking cessation. Evidence is encouraging but indication-specific and still maturing.